专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9823244A2 INTRACORONARY STENTS CONTAINING QUINAZOLINONE DERIVATIVES 审中-公开
标题翻译：含有喹唑啉酮衍生物的神经瘤
公开(公告)号：WO9823244A2
公开(公告)日：1998-06-04
申请号：PCT/US9715254
申请日：1997-08-14
申请人： AGRICULTURAL RES ORG , HADASIT MED RES SERVICE , DAVIDSON CLIFFORD M , NAGLER ARNON , SLAVIN SHIMON , HAZUM ELI , VLODAVSKY ISRAEL , GELLER EHUD , PINES MARK
发明人： DAVIDSON CLIFFORD M , NAGLER ARNON , SLAVIN SHIMON , HAZUM ELI , VLODAVSKY ISRAEL , GELLER EHUD , PINES MARK
IPC分类号： C07D401/06 , A61F2/06 , A61F2/82 , A61K31/506 , A61L27/00 , A61L31/10 , A61L31/16 , A61P9/00 , A61K
CPC分类号： A61L31/10 , A61F2/82 , A61K31/506 , A61L31/16 , A61L2300/216 , A61L2300/416 , A61L2300/606 , C08L31/04
摘要： The invention provides an intracoronary stent coated with a quinazolinone derivative of formula (I), wherein n is 1 or 2, R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and physiologically acceptable salts thereof, for preventing restenosis after angioplasty.
摘要翻译：本发明提供涂覆有式（I）的喹唑啉酮衍生物的冠状动脉内支架，其中n为1或2，R 1为氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基的成员; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员，R3是氢和低级烯氧基 - 羰基的成员及其生理上可接受的盐，用于防止血管成形术后的再狭窄。

2. 发明申请

WO0009070A3 INHIBITION OF PATHOGENIC PROCESSES RELATED TO TISSUE TRAUMA 审中-公开
标题翻译：与组织TRAUMA相关的致病过程的抑制
公开(公告)号：WO0009070A3
公开(公告)日：2000-10-19
申请号：PCT/IL9900440
申请日：1999-08-13
申请人： HADASIT MED RES SERVICE , AGRICULTURAL RES ORG , PINES MARK , VLODAVSKY ISRAEL , NAGLER ARNON , HAZUM ELI
发明人： PINES MARK , VLODAVSKY ISRAEL , NAGLER ARNON , HAZUM ELI
IPC分类号： G01N33/50 , A61K31/00 , A61K31/517 , A61K45/00 , A61K48/00 , A61P17/02 , A61P43/00 , G01N33/15 , A61K31/505
CPC分类号： A61K31/00
摘要： According to the present invention compositions and methods are provided to prevent the pathogenic aspects of tissue trauma while preserving normal tissue repair mechanisms, based on the fact that these molecules abrogate the cascade of damage initiated by tissue trauma, while maintaining this the requisite healthy extracellular matrix economy. The composition for regulating the extracellular matrix economy, comprise a pharmaceutically effective amount of an effector in combination with a pharmaceutically acceptable carrier. Preferably, the effector is a quinazolinone derivative. More preferably, the quinazolinone derivative is a member of a group having formula (I), wherein R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy; and pharmaceutically acceptable salts thereof; and n is either 1 or 2. Most preferably, the effector is Halofuginone and pharmaceutically acceptable salts thereof.
摘要翻译：根据本发明，提供了组合物和方法，以防止组织创伤的病态方面，同时保持正常组织修复机制，这是基于这些分子消除由组织创伤引起的损伤级联的事实，同时保持必需的健康细胞外基质经济。用于调节细胞外基质经济性的组合物包含与药学上可接受的载体组合的药学有效量的效应物。优选地，效应子是喹唑啉酮衍生物。更优选地，喹唑啉酮衍生物是具有式（I）的基团的成员，其中R 1是由氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基组成的组的成员; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员，R3是氢和低级链烯氧基的成员; 及其药学上可接受的盐; 并且n为1或2.最优选地，效应物是卤代酮及其药学上可接受的盐。

3. 发明申请

WO2008087650A3 COMPOSITION AND METHOD FOR TREATING OR PREVENTING SKELETAL MUSCLE FIBROSIS 审中-公开
标题翻译：用于治疗或预防骨骼肌肉纤维化的组合物和方法
公开(公告)号：WO2008087650A3
公开(公告)日：2009-12-30
申请号：PCT/IL2008000088
申请日：2008-01-21
申请人： AGRICULTURAL RES ORG , HADASIT MED RES SERVICE , PINES MARK , NAGLER ARNON
发明人： PINES MARK , NAGLER ARNON
IPC分类号： A61K31/519
CPC分类号： A61K31/517
摘要： A compound in combination with a pharmaceutically acceptable carrier, the compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2; and pharmaceutically acceptable salts thereof; for use in treatment of or prevention of skeletal muscle fibrosis and/or for inducing skeletal muscle regeneration.
摘要翻译：与药学上可接受的载体组合的化合物，所述化合物具有下式：其中：R 1是氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基的成员; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员; 并且R 3是由氢和低级链烯氧基 - 羰基组成的组的成员; n为1或2; 及其药学上可接受的盐; 用于治疗或预防骨骼肌纤维化和/或用于诱导骨骼肌再生。

4. 发明申请

WO02094178A2 TREATMENT OF RENAL FIBROSIS 审中-公开
标题翻译：治疗肾脏纤维化
公开(公告)号：WO02094178A2
公开(公告)日：2002-11-28
申请号：PCT/IL0200408
申请日：2002-05-23
申请人： HADASIT MED RES SERVICE , ISRAEL STATE , COLLGARD BIOPHARMACEUTICALS LT , NAGLER ARNON , VLODAVSKY ISRAEL , PINES MARK , YARKONI SHAI
发明人： NAGLER ARNON , VLODAVSKY ISRAEL , PINES MARK , YARKONI SHAI
IPC分类号： A61J1/03 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/495 , A61K31/517 , A61P3/10 , A61P9/12 , A61P13/12 , A61P37/06 , C07D401/06 , A61K
CPC分类号： A61K31/495
摘要： The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for treatment renal fibrosis, comprising as active ingredient a quinazolinone derivative as herein defined. The currently preferred embodiment is halofuginone, which is now show to slow or prevent progression of renal fibrosis in vivo , thereby preventing end-stage renal failure.
摘要翻译：本发明涉及含有喹唑啉酮的组合物。更具体地，本发明涉及用于治疗肾纤维化的组合物，其包含作为本文定义的喹唑啉酮衍生物的活性成分。目前优选的实施方案是卤夫酮，其现在显示为减缓或阻止体内肾纤维化的进展，从而防止终末期肾衰竭。

5. 发明专利

IL148246A COMPOSITIONS COMPRISING HALOFIGINONE DERIVATIVES FOR TREATING URETHRAL STRICTURE 未知
公开(公告)号：IL148246A
公开(公告)日：2008-11-26
申请号：IL14824602
申请日：2002-02-19
申请人： HADASIT MED RES SERVICE , VLODAVSKY ISRAEL , NAGLER ARNON , PINES MARK , STATE OF ISRAEL AGRICULTURAL R
发明人： VLODAVSKY ISRAEL , NAGLER ARNON , PINES MARK

7. 发明公开

EP0787000A4 QUINAZOLINONE PHARMACEUTICALS AND USE THEREOF 失效转让
标题翻译：喹唑啉酮药物及其用途
公开(公告)号：EP0787000A4
公开(公告)日：1997-11-12
申请号：EP95933731
申请日：1995-08-29
申请人： DAVIDSON CLIFFORD M , AGRICULTURAL RES ORG , HADASIT MED RES SERVICE
发明人： NAGLER ARNON , SLAVIN SHIMON , VLODAVSKY ISRAEL , PINES MARK
IPC分类号： C07D401/06 , A61K31/505 , A61K31/517 , A61P9/00 , A61P43/00
CPC分类号： A61K31/517

8. 发明申请

WO03059355A8 QUINAZOLINONE COMPOUNDS IN COMBINED MODALITIES FOR IMPROVED CANCER TREATMENT 审中-公开
标题翻译：用于改善癌症治疗的组合模式中的喹哪啶酮化合物
公开(公告)号：WO03059355A8
公开(公告)日：2004-07-29
申请号：PCT/IL0201055
申请日：2002-12-30
申请人： HADASIT MED RES SERVICE , INST OF ANIMAL SCIENCE AGRICUL , COLLGARD BIOPHARMACEUTICALS LT , VLODAVSKY ISRAEL , NAGLER ARNON , YARKONI SHAI
发明人： PINES MARK , VLODAVSKY ISRAEL , NAGLER ARNON , YARKONI SHAI
IPC分类号： C07D401/06 , A61K31/131 , A61K31/138 , A61K31/167 , A61K31/17 , A61K31/196 , A61K31/198 , A61K31/282 , A61K31/337 , A61K31/407 , A61K31/4164 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/57 , A61K31/675 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/24 , A61K38/00 , A61K38/04 , A61K38/21 , A61K38/43 , A61K45/00 , A61K45/06 , A61P35/00 , A61P43/00 , C07D239/88
CPC分类号： A61K45/06 , A61K31/517 , A61K2300/00
摘要： The present invention provides compositions and methods for improving the effectiveness of anti-tumor treatments. The compositions of the present invention comprise quinazolinones, specifically halofuginone. In currently preferred embodiments the compositions and methods of the present invention improve the effectiveness of radiation therapy and chemotherapy, and concomitantly alleviate or prevent the damage induced by radiation therapy.
摘要翻译：本发明提供了用于提高抗肿瘤治疗效果的组合物和方法。本发明的组合物包含喹唑啉酮，特别是卤夫酮。在目前优选的实施方案中，本发明的组合物和方法提高了放射治疗和化疗的有效性，并且同时缓解或预防了由放射治疗引起的损伤。

9. 发明申请

WO2004039308A2 QUINAZOLINONE COMPOSITIONS FOR REGULATION OF GENE EXPRESSION RELATED TO PATHOLOGICAL PROCESSES 审中-公开
标题翻译：喹唑啉酮调节基因表达的病理过程相关基因表达调控
公开(公告)号：WO2004039308A2
公开(公告)日：2004-05-13
申请号：PCT/IL0300900
申请日：2003-10-30
申请人： ISRAEL STATE , HADASIT MED RES SERVICE , COLLGARD BIOPHARMACEUTICALS LT , PINES MARK , NAGLER ARNON , YARKONI SHAI
发明人： PINES MARK , NAGLER ARNON , YARKONI SHAI
IPC分类号： A61K20060101 , A61K31/517 , A61K
CPC分类号： A61K31/517
摘要： The present invention relates to pharmaceutical compositions for modifying gene expression in a pathological process, thereby preventing or ameliorating said process. More particularly the compositions comprise quinazolinones, especially halofuginone, for inhibiting or preventing alterations in gene expression during fibrosis. The present invention particularly relates to pharmaceutical compositions for improving the regeneration of cirrhotic liver.
摘要翻译：本发明涉及用于在病理过程中修饰基因表达的药物组合物，由此预防或改善所述过程。更特别地，所述组合物包含喹唑啉酮，特别是卤夫酮，用于抑制或防止纤维化期间基因表达的改变。本发明特别涉及用于改善肝硬化再生的药物组合物。

10. 发明专利

CA2207097A1 QUINAZOLINONE-CONTAINING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE THEREOF 未知
公开(公告)号：CA2207097A1
公开(公告)日：1996-06-27
申请号：CA2207097
申请日：1995-12-21
申请人： DAVIDSON CLIFFORD M , AGRICULTURAL RES ORG , HADASIT MED RES SERVICE
发明人： SLAVIN SHIMON , VLODAVSKY ISRAEL , NAGLER ARNON , PINES MARK
IPC分类号： C07D401/06 , A61K31/4545 , A61K31/505 , A61P43/00
摘要： The invention provides a composition for attenuating mesangial cell proliferation, comprising an amount of a compound of formula (I) wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; effective to attenuate mesangial cell proliferation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式